BFEC
AIMT

Benjamin F. Edwards & Company’s Aimmune Therapeutics AIMT Stock Holding History

Benjamin F. Edwards & Company’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$3K – 1793
2018
Q3 		$3K Hold
100
– – ﹤0.01% 1504
2018
Q2 		$3K Hold
100
– – ﹤0.01% 1500
2018
Q1 		$3K Buy
+100
New +$3.52K ﹤0.01% 1502

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Benjamin F. Edwards & Company's AIMT Position: Q4 2018 in Review

Benjamin F. Edwards & Company sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 100 shares — an estimated $3K sold.

Benjamin F. Edwards & Company first reported a position in AIMT in Q1 2018 and held it in 3 quarters. The position peaked at $3K in Q3 2018. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

  • Benjamin F. Edwards & Company reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 100 Aimmune Therapeutics shares in Q4 2018, an estimated $3K.
  • Benjamin F. Edwards & Company first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 3 quarters.
  • Benjamin F. Edwards & Company's Aimmune Therapeutics position peaked at $3K in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2018, filed 31 Jan 2019.